Nasmed Ozel Saglik Hizmetleri Ticaret AS vs HCA Healthcare: Fair Value & Quality
Both stocks run through our valuation models. Here is how Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) and HCA Healthcare (HCA) compare, as of Aug 8, 2026.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
HCA Healthcare leads: 4 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Nasmed Ozel Saglik Hizmetleri Ticaret AS
7 of 15 models see the stock below the current price.
HCA Healthcare
6 of 23 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Nasmed Ozel Saglik Hizmetleri Ticaret AS · Health Care
HCA Healthcare · Health Care
Bottom line
As of Aug 8, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Nasmed Ozel Saglik Hizmetleri Ticaret AS trades at TRY 18.74 versus a fair value of TRY 11.92 (-36%), while HCA Healthcare trades at $413 versus $555 (+34%).
HCA Healthcare has the higher quality score (62/100).
See the full analysis →More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Related to Nasmed Ozel Saglik Hizmetleri Ticaret AS
Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & CompanySee the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.